Precision Oncology and Cancer Biomarkers Issues at Stake and Matters of Concern /

This open access book reflects on matters of social and ethical concern raised in the daily practices of those working in and around precision oncology. Each chapter addresses the experiences, concerns and issues at stake for people who work in settings where precision oncology is practiced, enacted...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Bremer, Anne (Editor), Strand, Roger (Editor)
Format: Electronic eBook
Language:English
Published: Cham : Springer International Publishing : Imprint: Springer, 2022.
Edition:1st ed. 2022.
Series:Human Perspectives in Health Sciences and Technology, 5
Subjects:
Online Access:Link to Metadata
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000nam a22000005i 4500
001 978-3-030-92612-0
003 DE-He213
005 20240316005835.0
007 cr nn 008mamaa
008 220329s2022 sz | s |||| 0|eng d
020 |a 9783030926120  |9 978-3-030-92612-0 
024 7 |a 10.1007/978-3-030-92612-0  |2 doi 
050 4 |a R723-723.7 
072 7 |a HP  |2 bicssc 
072 7 |a MBDC  |2 bicssc 
072 7 |a MED050000  |2 bisacsh 
072 7 |a QD  |2 thema 
072 7 |a MBDC  |2 thema 
082 0 4 |a 610.1  |2 23 
245 1 0 |a Precision Oncology and Cancer Biomarkers  |h [electronic resource] :  |b Issues at Stake and Matters of Concern /  |c edited by Anne Bremer, Roger Strand. 
250 |a 1st ed. 2022. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2022. 
300 |a XIV, 281 p. 1 illus.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Human Perspectives in Health Sciences and Technology,  |x 2661-8923 ;  |v 5 
505 0 |a Introduction (Anne Bremer and Roger Strand) -- Chapter 1. Precision oncology in the news (Mille Stenmarck and Irmelin Nilsen) -- Chapter 2. Cancer biomarkers from a patient's perspective (Karen Gissum) -- Chapter 3. Breast cancer: reconstruction of trouble (Hanna Dillekås) -- Chapter 4. HER2: an apparently 'simple' biomarkers revealing the complexities and uncertainties of precision oncology (Elisabeth Wik, Anne Bremer and Lars A. Akslen) -- Chapter 5. Integrating genomic and non-genomic factors in shaping the personal fingerprint in personalised cancer treatments (Mariano Bizzari and Andrea Pensotti) -- Chapter 6. Systems medicine and perspectives on precision oncology (Rune Kleppe, Inge Jonassen and Roger Strand) -- Chapter 7. Precision oncology: the challenges related to publishing (Maria Lie Lotsberg) -- Chapter 8. Filled with Desire, Perceive Molecules (Caroline Engen and Roger Strand) -- Chapter 9. Precision health and ethical ambiguity: How much cancer can we afford to prevent? (Leonard Fleck) -- Chapter 10. New cancer drugs and the public controversy: how can biomarkers contribute? (Eirik Tranvåg and Roger Strand) -- Chapter 11. Assessing the cost-effectiveness of targeted therapies and checkpoint inhibitors (John Cairns) -- Chapter 12. Real-world data in Health Technology Assessment of targeted cancer therapy (Jiyeon Kang) -- Chapter 13. Negotiating safety and resources in a first in human cancer trial in Denmark (Line Hillersdal) -- Conclusion: Precision oncology: Fact or fantasy? (Roger Strand and Anne Bremer). 
506 0 |a Open Access 
520 |a This open access book reflects on matters of social and ethical concern raised in the daily practices of those working in and around precision oncology. Each chapter addresses the experiences, concerns and issues at stake for people who work in settings where precision oncology is practiced, enacted, imagined or discussed. It subsequently discusses and analyses bioethical dilemmas, scientific challenges and economic trade-offs, the need for new policies, further technological innovation, social work, as well as phenomenological research. This volume takes a broad actor-centred perspective as, whenever cancer is present, the range of actors with issues at stake appears almost unlimited. This perspective and approach opens up the possibility for further in-depth and diverse questions, posed by the actors themselves, such as: How are cancer researchers navigating biological uncertainties? How do clinicians and policy-makers address ethical dilemmas around prioritisation ofcare? What are the patients' experiences with, and hopes for, precision oncology? How do policy-makers and entrepreneurs envisage precision oncology? These questions are of great interest to a broad audience, including cancer researchers, oncologists, policy-makers, medical ethicists and philosophers, social scientists, patients and health economists. 
650 0 |a Medicine  |x Philosophy. 
650 0 |a Bioethics. 
650 0 |a Cancer. 
650 0 |a Public health. 
650 0 |a Medical economics. 
650 1 4 |a Philosophy of Medicine. 
650 2 4 |a Bioethics. 
650 2 4 |a Cancer Biology. 
650 2 4 |a Public Health. 
650 2 4 |a Health Economics. 
700 1 |a Bremer, Anne.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Strand, Roger.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783030926113 
776 0 8 |i Printed edition:  |z 9783030926137 
776 0 8 |i Printed edition:  |z 9783030926144 
830 0 |a Human Perspectives in Health Sciences and Technology,  |x 2661-8923 ;  |v 5 
856 4 0 |u https://doi.org/10.1007/978-3-030-92612-0  |z Link to Metadata 
912 |a ZDB-2-REP 
912 |a ZDB-2-SXPR 
912 |a ZDB-2-SOB 
950 |a Religion and Philosophy (SpringerNature-41175) 
950 |a Philosophy and Religion (R0) (SpringerNature-43725)